World's Smallest Pacemaker and Investigational Insulin Pump System Recognized Among the Top 100 Technology Innovations
DUBLIN - November 18, 2015 - Medtronic plc (NYSE: MDT) today announced that its Micra® Transcatheter Pacing System (TPS) and Hybrid Closed Loop system have both earned the 2015 'Best of What's New' award in the health category by Popular Science, the world's largest science and technology magazine.
Selected after careful evaluation of thousands of submissions, the Micra TPS and Hybrid Closed Loop system, which includes an insulin pump and a continuous glucose monitor sensor, are among the 100 honorees that represent a significant leap forward in their respective categories. All winners will be featured in the magazine's December issue, available now.
At less than one-tenth the size of traditional pacemakers, the Micra TPS is the world's smallest pacemaker yet provides the most advanced pacing technology available for patients. It is cosmetically invisible and small enough to be delivered with minimally invasive techniques through a catheter, and implanted directly into the heart. Comparable in size to a large vitamin, the Micra TPS does not require the use of wires, known as "leads," to deliver pacing therapy; rather, its flexible tines attach to the interior of the right ventricle. In the United States, the Micra TPS is an investigational device and not yet approved for commercial use. The device was awarded CE Mark (Conformité Européenne) in April 2015, with approval for 1.5T and 3T full body MRI scanning providing patients with access to the most advanced imaging diagnostic procedures.
Building on the breakthrough technology in the MiniMed® 640G system (investigational device in the United States, commercially available in select countries outside of the United States), the Hybrid Closed Loop system is designed to automatically control glucose levels 24 hours a day with less input from people with diabetes. People using the system will only need to enter their carbohydrates at mealtime, and calibrate the sensor periodically, significantly simplifying today's diabetes management routines. The Hybrid Closed Loop system is an investigational device and not yet approved for commercial use. The technology is currently in the first pivotal trial of closed loop technology conducted in the United States. As Medtronic's largest and longest at-home closed loop study, this single-arm, multi-center, home and hotel clinical study will enroll up to 150 patients aged 14-75 with type 1 diabetes on insulin pump therapy. Additional trial details, including enrollment information, can be found at ClinicalTrials.gov (Identifier: NCT02463097).
"The Best of What's New awards honor the innovations that surprise and amaze us-those that challenge our view of what's possible in the future," said Cliff Ransom, Editor-in-Chief of Popular Science. "The award is Popular Science's top prize, and the 100 winners-chosen from among thousands of nominees-are each a revolution in their respective fields."
About Best of What's New
Each year, the editors of Popular Science review thousands of products in search of the top 100 tech innovations of the year-breakthrough products and technologies that represent a significant leap in their categories. The winners, the Best of What's New, are awarded inclusion in the much-anticipated December issue of Popular Science, the most widely read issue of the year since the debut of Best of What's New in 1988. Best of What's New awards are presented to 100 new products and technologies in 12 categories: Automotive, Aviation, Computing, Engineering, Gadgets, Green, Entertainment, Security, Software, Home, Health and Recreation.
About Popular Science
Founded in 1872, Popular Science is the world's largest science and technology magazine; with a circulation of 1.3 million and 6.8 million monthly readers. Each month, Popular Science reports on the intersection of science and everyday life, with an eye toward what's new and why it matters. Popular Science is published by Bonnier Active Media, a subsidiary of Bonnier Corporation.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
-end-
Contacts:
Ryan Mathre
Public Relations
Cardiac and Vascular Group
+1-763-514-9625
Pamela Reese
Communications
Diabetes Group
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1967564